Free Trial

Edwards Lifesciences (EW) Stock Price, News & Analysis

Edwards Lifesciences logo
$69.75 -0.78 (-1.11%)
(As of 12:04 PM ET)

About Edwards Lifesciences Stock (NYSE:EW)

Key Stats

Today's Range
$69.60
$70.57
50-Day Range
$64.54
$72.07
52-Week Range
$58.93
$96.12
Volume
1.06 million shs
Average Volume
4.62 million shs
Market Capitalization
$41.14 billion
P/E Ratio
10.06
Dividend Yield
N/A
Price Target
$77.25
Consensus Rating
Hold

Company Overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
93rd Percentile Overall Score

EW MarketRank™: 

Edwards Lifesciences scored higher than 93% of companies evaluated by MarketBeat, and ranked 102nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Edwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 10 buy ratings, 16 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Edwards Lifesciences has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Edwards Lifesciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Edwards Lifesciences are expected to decrease by -5.06% in the coming year, from $2.57 to $2.44 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Edwards Lifesciences is 10.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.07.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Edwards Lifesciences is 10.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.71.

  • Price to Earnings Growth Ratio

    Edwards Lifesciences has a PEG Ratio of 4.01. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Edwards Lifesciences has a P/B Ratio of 6.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Edwards Lifesciences' valuation and earnings.
  • Percentage of Shares Shorted

    1.18% of the float of Edwards Lifesciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Edwards Lifesciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Edwards Lifesciences has recently decreased by 10.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Edwards Lifesciences does not currently pay a dividend.

  • Dividend Growth

    Edwards Lifesciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.18% of the float of Edwards Lifesciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Edwards Lifesciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Edwards Lifesciences has recently decreased by 10.78%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Edwards Lifesciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 87 news articles for Edwards Lifesciences this week, compared to 19 articles on an average week.
  • Search Interest

    Only 4 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,657,000.00 in company stock.

  • Percentage Held by Insiders

    Only 1.27% of the stock of Edwards Lifesciences is held by insiders.

  • Percentage Held by Institutions

    79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Edwards Lifesciences' insider trading history.
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
See More Headlines

EW Stock Analysis - Frequently Asked Questions

Edwards Lifesciences' stock was trading at $76.25 at the beginning of the year. Since then, EW shares have decreased by 8.2% and is now trading at $69.96.
View the best growth stocks for 2024 here
.

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings results on Thursday, October, 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences's quarterly revenue was up 8.9% compared to the same quarter last year.
Read the conference call transcript
.

Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and more.

Edwards Lifesciences' top institutional investors include Wellington Management Group LLP (5.35%), State Street Corp (4.45%), Geode Capital Management LLC (2.29%) and Fisher Asset Management LLC (1.54%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Bernard J Zovighian, Kieran Gallahue, Donald E Bobo Jr, Catherine M Szyman, Scott B Ullem, Daveen Chopra, Heisz Leslie Stone, Martha H Marsh, Daniel J Lippis, Robert WA Sellers, Michael A Mussallem and Huimin Wang.
View institutional ownership trends
.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol-Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto-Dominion Bank (TD).

Company Calendar

Last Earnings
10/24/2024
Today
12/03/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/04/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
28176E10
Employees
19,800
Year Founded
1958

Price Target and Rating

Average Stock Price Target
$77.25
High Stock Price Target
$105.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+9.5%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
26 Analysts

Profitability

Net Income
$1.40 billion
Pretax Margin
29.55%

Debt

Sales & Book Value

Annual Sales
$6.00 billion
Cash Flow
$2.73 per share
Book Value
$16.30 per share

Miscellaneous

Free Float
582,192,000
Market Cap
$41.60 billion
Optionable
Optionable
Beta
1.12

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NYSE:EW) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners